Melanoma/Skin Cancer

Top Story

Ipilimumab plus T-VEC shows promise for metastatic melanoma

Ipilimumab plus T-VEC shows promise for metastatic melanoma
June 27, 2016

Talimogene laherparepvec plus ipilimumab demonstrated safety and efficacy among patients with untreated, unresectable advanced melanoma, according to study results published in Journal of Clinical Oncology.

“Tumor immunotherapy has become an established treatment of metastatic melanoma and is being increasingly applied to other cancer types,” Igor Puzanov, MD, MSCI, associate professor of medicine at Vanderbilt University School of Medicine, and colleagues wrote. “A hallmark of tumors likely to respond to immunotherapy is a lymphocyte-predominant tumor microenvironment. To date, immunotherapy designed to promote lymphocyte accumulation within established tumors, activate lymphocyte function and cytotoxicity, and prevent T-cell suppression has shown the most promise.”

In the Journals

Socioeconomic factors might be associated with occupational risk of cutaneous SCC

June 24, 2016
Socioeconomic factors and occupational exposures might be associated with an occupational variation in the risk for cutaneous squamous cell carcinoma, according to…
In the Journals

Pembrolizumab shows activity in brain metastases from NSCLC, melanoma

June 24, 2016
Pembrolizumab demonstrated therapeutic activity in brain metastases of patients with non–small cell lung cancer or melanoma, according to early results of an…
At IssueVideo

VIDEO: Toxicities related to immune therapies ‘unpredictable’ but ‘manageable’

June 23, 2016
James P. Allison, PhD, chair of the department of immunology and executive director of the immunotherapy platform at MD Anderson Cancer Center in Houston, discusses…
CME

Updates in Melanoma 2015: Entering a New Therapeutic Era

This activity is supported by an educational grant from Merck & Co., Inc.

The incidence of melanoma, an aggressive disease that accounts for approximately 75% of skin-cancer-related deaths, is…
More »
Video
Meeting News Coverage

VIDEO: Merge of immunotherapy, genomics lead to personalized treatment

June 23, 2016
More »
Featured
2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

CME Video

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »
In the Journals

Ipilimumab plus T-VEC shows promise for metastatic melanoma

June 27, 2016
Talimogene laherparepvec plus ipilimumab demonstrated safety and efficacy among patients with untreated, unresectable advanced melanoma, according to…

In the Journals

Socioeconomic factors might be associated with occupational risk of cutaneous SCC

June 24, 2016
Socioeconomic factors and occupational exposures might be associated with an occupational variation in the risk for cutaneous squamous cell…

In the Journals

Pembrolizumab shows activity in brain metastases from NSCLC, melanoma

June 24, 2016
Pembrolizumab demonstrated therapeutic activity in brain metastases of patients with non–small cell lung cancer or melanoma, according to early…

At IssueVideo

VIDEO: Toxicities related to immune therapies ‘unpredictable’ but ‘manageable’

June 23, 2016
James P. Allison, PhD, chair of the department of immunology and executive director of the immunotherapy platform at MD Anderson Cancer Center in…

Meeting News CoverageVideo

VIDEO: Merge of immunotherapy, genomics lead to personalized treatment

June 23, 2016
CHICAGO — Candace Johnson, PhD, president and CEO of Roswell Park Cancer Institute, discusses how research in immunotherapy and genomics can…

Video

VIDEO: Study examines pembrolizumab in combination with ipilimumab or interferon for melanoma, renal cell carcinoma

June 22, 2016
In this video, Michael B. Atkins, MD, of Georgetown University School of Medicine and the Georgetown-Lombardi Comprehensive Cancer Center in…

Meeting News CoverageVideo

VIDEO: Diabetes, obesity associated with chemotherapy-induced neuropathy

June 22, 2016
CHICAGO — Dawn L. Hershman, MD, MS, associate professor of medicine at Columbia University Medical Center, reviews study results that…

Meeting News CoveragePerspective

Pembrolizumab plus ipilimumab safe, effective for advanced melanoma

June 21, 2016
CHICAGO — Combined treatment with pembrolizumab and ipilimumab demonstrated robust antitumor activity and acceptable toxicity in patients with…

White Out Cancer Day increases awareness of cancer immunotherapy

June 17, 2016
Employees of SLACK Incorporated — publisher of HemOnc Today — wore white today in support of White Out Cancer Day. The Cancer Research…

12 advances in cancer immunotherapy

June 17, 2016
Today marks White Out Cancer Day. The Cancer Research Institute launched the observance four years ago, encouraging people to wear white to raise…

More Headlines »
morganatic-roan
morganatic-roan